Q4 25 EPS
$-0.32
BEAT +19.17%
Est. $-0.40
Q4 25 Revenue
$7.0M
BEAT +61.41%
Est. $4.3M
vs S&P Since Q4 25
+86.4%
BEATING MARKET
RLAY +94.1% vs S&P +7.7%
Full Year 2025 Results
FY 25 EPS
$-1.61
FY 25 Revenue
$15.4M
Market Reaction
Did RLAY Beat Earnings? Q4 2025 Results
Relay Therapeutics delivered a strong finish to fiscal 2025, beating Wall Street expectations on both the top and bottom lines as its pipeline progress and leaner cost structure took hold. The clinical-stage biotech posted a Q4 loss per share of $0.3… Read more Relay Therapeutics delivered a strong finish to fiscal 2025, beating Wall Street expectations on both the top and bottom lines as its pipeline progress and leaner cost structure took hold. The clinical-stage biotech posted a Q4 loss per share of $0.32, coming in 19.17% better than the consensus estimate of $0.40, while revenue of $7.00 million cleared the $4.34 million analyst forecast by 61.41%, driven largely by recognition of payments under its Exclusive License Agreement with Elevar Therapeutics. The net loss narrowed to $54.89 million from $76.00 million a year earlier, reflecting meaningful cuts to R&D and G&A spending following the company's 2024-2025 research restructuring. Shares surged roughly 19% to a 52-week high in the wake of the report, buoyed further by FDA Breakthrough Therapy designation for lead asset zovegalisib. With $554.52 million in cash and investments on hand, management projects a runway into 2029, and investors are watching closely for Phase 1/2 zovegalisib data at ESMO TAT in March 2026 as the next major catalyst.
Key Takeaways
- • Revenue recognized under Exclusive License Agreement with Elevar Therapeutics for lirafugratinib
- • Reduced R&D and G&A expenses from research organization streamlining in 2024-2025
- • Lower stock compensation expense and employee costs
RLAY YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
“Our focus on disciplined execution to date has strengthened the foundation of Relay, aligning our organization to support long-term success. In 2026, Relay is entering a pivotal period defined by multiple upcoming clinical milestones across our zovegalisib program, which recently received Breakthrough Therapy designation from the FDA.”
— Sanjiv Patel, Q4 2025 Earnings Press Release
RLAY Earnings Trends
RLAY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RLAY EPS Trend
Earnings per share: estimate vs actual
RLAY Revenue Trend
Quarterly revenue: estimate vs actual
RLAY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.36 | $-0.41 | -15.01% | $3.0M | -35.48% |
| Q4 25 BEAT FY | $-0.40 | $-0.32 | +19.17% | $7.0M | +61.41% |
| FY Full Year | — | $-1.61 | — | $15.4M | — |
| Q3 25 MISS | $-0.42 | $-0.43 | -2.75% | $0 | -100.00% |
| Q2 25 BEAT | $-0.44 | $-0.41 | +7.66% | $677,000 | +4,637.58% |
| Q1 25 BEAT | $-0.48 | $-0.46 | +4.11% | $7.7M | +69,017.91% |